Girerd, N. et al. (2023) Protein biomarkers of new-onset heart failure: insights from the Heart Omics and Ageing cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study. Circulation: Heart Failure, 16(5), pp. 426-441. (doi: 10.1161/CIRCHEARTFAILURE.122.009694) (PMID:37192292) (PMCID:PMC10179982)

Kobayashi, M. et al. (2023) A machine learning derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: findings from the HOMAGE trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.2859) (Early Online Publication)

Ferreira, J. P. et al. (2023) Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: pooled analysis of three randomized trials. International Journal of Cardiology, 377, pp. 86-88. (doi: 10.1016/j.ijcard.2023.01.088) (PMID:36738846)

Ferreira, J. P. et al. (2023) Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials. European Journal of Heart Failure, 25(1), pp. 108-113. (doi: 10.1002/ejhf.2726) (PMID:36303266)

Rossignol, P. et al. (2022) NT-proBNP and stem cell factor plasma concentrations are independently associated with cardiovascular outcomes in end-stage renal disease hemodialysis patients. European Heart Journal Open, 2(6), oeac069. (doi: 10.1093/ehjopen/oeac069) (PMID:36600882) (PMCID:PMC9797490)

Kobayashi, M. et al. (2022) The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial. European Journal of Heart Failure, 24(9), pp. 1559-1568. (doi: 10.1002/ejhf.2579) (PMID:35703355)

Verdonschot, J. A.J. et al. (2022) The effect of spironolactone in patients with obesity at risk for heart failure: proteomic insights from the HOMAGE trial. Journal of Cardiac Failure, 28(5), pp. 778-786. (doi: 10.1016/j.cardfail.2021.12.005) (PMID:34933097)

Ferreira, J. P., Girerd, N., Rocca, H.-P. B.-L., Pellicori, P. , Cleland, J. G. , Rossignol, P. and Zannad, F. (2021) No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial = Pas d’influence de la spironolactone sur les concentrations plasmatiques de l’enzyme de conversion de l’angiotensine 2 : résultats de l’essai randomisé HOMAGE. Archives of Cardiovascular Diseases, 114(12), pp. 814-817. (doi: 10.1016/j.acvd.2021.10.003) (PMID:34772647) (PMCID:PMC8576594)

Cuthbert, J. J., Pellicori, P. , Flockton, R., Kallvikbacka-Bennett, A., Khan, J., Rigby, A. S., Girerd, N., Zannad, F., Cleland, J. G.F. and Clark, A. L. (2021) The prevalence and clinical associations of ultrasound measures of congestion in patients at risk of developing heart failure. European Journal of Heart Failure, 23(11), pp. 1831-1840. (doi: 10.1002/ejhf.2353) (PMID:34632680)

Verdonschot, J. A.J. et al. (2021) Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. Cardiovascular Diabetology, 20, 163. (doi: 10.1186/s12933-021-01357-9)

Cleland, J. G.F. et al. (2021) The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. European Heart Journal, 42(6), pp. 684-696. (doi: 10.1093/eurheartj/ehaa758) (PMID:33215209) (PMCID:PMC7878013)

Pellicori, P. et al. (2020) Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof‐of‐concept, randomised, precision‐medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. European Journal of Heart Failure, 22(9), pp. 1711-1723. (doi: 10.1002/ejhf.1716) (PMID:31950604)

Huang, Q.-F. et al. (2018) Urinary proteomic signatures associated with β-blockade and heart rate in heart transplant recipients. PLoS ONE, 13(9), e0204439. (doi: 10.1371/journal.pone.0204439) (PMID:30248148) (PMCID:PMC6152976)